1,2,3-Triazolyl ester of Ketorolac: A “Click Chemistry”-based highly potent PAK1-blocking cancer-killer
Author:
Publisher
Elsevier BV
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference15 articles.
1. Herbal therapeutics that block the oncogenic kinase PAK1: a practical approach towards PAK1-dependent diseases and longevity;Maruta;Phytother. Res.,2014
2. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance;Hirokawa;Cancer Biol. Ther.,2005
3. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors);Hirokawa;Cancer Lett.,2007
4. R-Ketorolac targets Cdc42 and Rac1 and alters ovarian cancer cell behaviors critical for invasion and metastasis;Guo;Mol. Cancer Ther.,2015
5. Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression;Wu;Int. J. Cancer,2010
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Rapamycin <i>vs</i> TORin-1 or Gleevec <i>vs</i> Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or <i>vice versa</i>?;Drug Discoveries & Therapeutics;2024-04-30
2. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions;Journal of Pharmacological Sciences;2023-05
3. Recent Advancements in Triazole-based Click Chemistry in Cancer Drug Discovery and Development;SynOpen;2023-05
4. Pyrrolizine/indolizine-bearing (un)substituted isoindole moiety: design, synthesis, antiproliferative and MDR reversal activities, and in silico studies;RSC Advances;2023
5. Antioxidant, anti-inflammatory and anti-acne activities of stingless bee (Tetragonula biroi) propolis;Fitoterapia;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3